<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941745</url>
  </required_header>
  <id_info>
    <org_study_id>rhCC10 Study 2013</org_study_id>
    <secondary_id>Grant #3899</secondary_id>
    <nct_id>NCT01941745</nct_id>
  </id_info>
  <brief_title>Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome</brief_title>
  <official_title>Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Therabron Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SP ZOZ Szpital Uniwersytecki w Krakowie Oddizat Neonatologii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result
      of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical
      ventilation and infection. These conditions initiate an inflammatory response characterized
      by elevated inflammatory cell infiltrates and proinflammatory cytokines that lead to the
      development of significant acute and chronic lung injury.

      The study drug, rhCC10, is a recombinant version of natural human CC10 protein. Native CC10
      is produced primarily by non-ciliated respiratory epithelial cells, called Clara cells and is
      the most abundant protein in the mucosal fluids in normal healthy lungs.

      The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and
      anti-inflammatory effects of a single intratracheal (IT) dose of rhCC10 to intubated
      premature infants receiving positive pressure ventilation for treatment of respiratory
      distress syndrome (RDS) to prevent long term respiratory complications referred to as
      bronchopulmonary dysplasia, and, more recently, as Chronic Pulmonary Insufficiency of
      Prematurity (CPIP; asthma, cough, wheezing, multiple respiratory infections).

      CC10 regulates inflammatory responses and protects the structural integrity of pulmonary
      tissue while preserving pulmonary mechanical function during various insults (eg. viral
      infection, bacterial endotoxin, ozone, allergens, hyperoxia). Together these properties
      suggest that administration of rhCC10 may help to facilitate development of normal airway
      epithelia and prevent the inflammation that leads to CPIP in these infants.

      This study is funded by the FDA Office of Orphan Product Development (OOPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant human CC10 protein (rhCC10) is a novel therapeutic agent used to prevent the
      development of chronic respiratory morbidity (CPIP; repeated respiratory infections, asthma,
      re-hospitalizations) in preterm infants. Native CC10 is a natural anti-inflammatory and
      immunomodulatory factor produced by Clara Cells in the lung and is the most abundant protein
      in respiratory mucosa. Animal data demonstrate that a single intratracheal dose of rhCC10
      administered shortly after birth reduces lung inflammation (important biomarkers linked to
      lung injury in preterm infants), promotes normal lung development, preserves lung
      architecture, improves pulmonary function, suppresses the response to endotoxin and enhances
      resistance to pulmonary infections. In preterm infants who die or develop lung inflammation
      and subsequent bronchopulmonary dysplasia (BPD), both the concentration and activity of CC10
      are significantly reduced indicating that CC10 is essential for preventing lung injury and
      promoting normal lung development. In a small phase I study, rhCC10 significantly decreased
      several indices of pulmonary inflammation in the lungs of premature infants who were at risk
      of developing BPD and associated CPIP. The drug appeared to be safe, well-tolerated, and
      reduce risk of re-hospitalization due to respiratory illness for 9-10 months after a single
      intratracheal dose at the time of birth (0/11 rhCC10-treated infants vs. 3/6
      placebo-treated). This supports the protective role of rhCC10 against damage from hyperoxia,
      mechanical ventilation, inflammation, and infection in the immature lung. A more normal
      airway epithelium will produce significantly more endogenous CC10, with both factors
      contributing to enhanced resistance to infections, less asthma, and improved long-term
      respiratory outcome. We propose to conduct a Phase 2 clinical trial to evaluate rhCC10 in
      extremely premature infants (&lt;29 weeks gestation) for the prevention of BPD and CPIP. This
      will be a randomized, double-blind, placebo-controlled dose escalation study in 88 premature
      infants. A single intratracheal dose of study drug (rhCC10 or placebo) will be administered
      to preterm infants receiving surfactant and mechanical ventilation for treatment of RDS.
      Infants will be followed to evaluate safety, pharmacokinetics, and short and long term
      efficacy of this approach. Safety will be evaluated through serious adverse event (SAE) and
      adverse event monitoring and by Bayley neurodevelopmental assessments at 18 months corrected
      gestational age (CGA). Efficacy measurements will include the primary combined endpoint of
      alive without evidence of CPIP through 12 months CGA (defined by parental diaries and
      pulmonary questionnaires) comparing rhCC10 treated to placebo controls. The availability of a
      therapy which prevents lung injury, promotes lung development, and prevents serious
      respiratory infections and asthma in high risk preterm infants would be a highly significant
      advancement in care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">August 25, 2017</completion_date>
  <primary_completion_date type="Actual">August 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA)</measure>
    <time_frame>12 Months Corrected Gestational Age (*no imputation for missing data)</time_frame>
    <description>Number of events of survived participants without one or more of the CPIP components defined below:
Medical/ER visits (CPIP-DV): At least one non-routine medical visit for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): One or more re-hospitalizations for respiratory causes.
Respiratory Symptoms (CPIP-SS): Evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications by parental diaries or pulmonary questionnaires.
Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen).
CPIP is defined as the presence of one or more parent-reported outcomes at 12 months CGA, validated by Respiratory diaries (presence of wheezing, coughing, and/or respiratory medication use ≥2 days per week for 3 consecutive weeks), and Pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long Term Efficacy - Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 6 Months Corrected Gestational Age (CGA)</measure>
    <time_frame>6 months Corrected Gestational Age</time_frame>
    <description>Number of events of survived participants, graded as not having 1, 2, 3, or 4 of the CPIP components defined below:
Medical/ER visits (CPIP-DV): ≥1 non-routine medical visit(s) for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): ≥1 re-hospitalization(s) for respiratory causes Respiratory Symptoms (CPIP-SS): Parent-reported evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen)
A participant graded without 4 CPIP components is considered in better health than a participant graded without 1 CPIP component. CPIP components were parent-validated via respiratory diaries (wheezing, coughing, and/or respiratory medication use ≥2 days/wk for 3 consecutive wks), and pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Efficacy - Number of Participants With Adverse Events</measure>
    <time_frame>Adverse events are monitored through 36 wks post-menstrual age (PMA)</time_frame>
    <description>The safety of the study drug was assessed by accounting the number of participants with Adverse Events (AEs) in the treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term Efficacy - Number of Neonates With Oxygen Requirement at 36 Weeks Post Menstrual Age</measure>
    <time_frame>36 weeks post-menstrual age</time_frame>
    <description>Short term efficacy evaluations involve number of neonates with oxygen requirement at 36 weeks post menstrual age.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Respiratory Distress Syndrome in Premature Infant</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>half normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of half normal saline at 2 ml/kg given intratracheally times one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose rhCC10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose rhCC10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half normal saline</intervention_name>
    <description>2 ml/kg</description>
    <arm_group_label>half normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose rhCC10</intervention_name>
    <description>1.5 mg/kg study drug (rhCC10)</description>
    <arm_group_label>Low Dose rhCC10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose rhCC10</intervention_name>
    <description>5 mg/kg in 2 ml/kg</description>
    <arm_group_label>High dose rhCC10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age less than or equal to 24 hours;

          -  Birth weight 600 - 1250 grams;

          -  Gestational age 24-29 weeks (not less than 24 weeks); at birth based on best estimate
             using obstetrical sonography (first or second trimester), solid dating criteria, or
             Ballard examination;

          -  Birth weight appropriate for gestational age;

          -  5 minute Apgar score &gt;5;

          -  Diagnosis of neonatal RDS based on clinical and radiographic criteria;

          -  Requiring intubation and mechanical ventilation for treatment of RDS;

          -  Received at least one dose of surfactant (prophylaxis or rescue); and

          -  Written informed consent is obtained from at least one of the infant's parents or
             legal guardians (see section 6.2) prior to enrollment of the subject. The parent(s) or
             legal guardian(s) must agree to all study-related procedures and evaluations.

        Exclusion Criteria:

          -  5 minute Apgar score of ≤ 5;

          -  Major congenital anomaly (chromosomal, renal, cardiac, hepatic, neurologic, or
             pulmonary malformations; minor anomalies such as cleft lip/palate are permitted);

          -  Evidence of severe neonatal depression (as defined by cord blood acid-base balance
             (pH) ≤ 7.00 and/or an Apgar score of &lt; 4 at 10 minutes);

          -  Evidence of congenital infection;

          -  Requires a major surgical procedure prior to administration of Study drug

          -  Enrollment in any other study involving administration of another investigational
             drug;

          -  Any condition which could preclude receiving study drug or performing any
             study-related procedures;

          -  Use of postnatal corticosteroids prior to administration of r-hCC10, except as
             specified in the protocol;

          -  Use of inhaled nitric oxide prior to administration of r-hCC10;

          -  Mother is known to be seropositive for HIV (per maternal medical records);

          -  Parent or guardian is unable or unwilling to complete the study diary;

          -  Parent or guardian is unable to bring the infant back to the study center for
             follow-up evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>29 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Parad, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <results_first_submitted>July 2, 2019</results_first_submitted>
  <results_first_submitted_qc>August 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2019</results_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01941745/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment spanned October 2013 - August 2017 at ICUs at Tufts Medical Center (Boston, MA), Brigham and Women's Hospital (Boston, MA), and BayState Medical Center (Springfield, MA). Three hospital sites in Poland were later added for the second high-dose/high dose placebo cohort of 44 neonates.</recruitment_details>
      <pre_assignment_details>No washout/run-in events to report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Associated w/ Low Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="P2">
          <title>Low Dose (rhCC10)</title>
          <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Associated w/ High Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 21 participants</description>
        </group>
        <group group_id="P4">
          <title>High Dose (rhCC10)</title>
          <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline populations were recruited from Tufts Medical Center and Brigham and Women’s Hospital. Sites with a second high-dose cohort include BayState Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (US, Poland).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Associated w/ Low Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="B2">
          <title>Low Dose (rhCC10)</title>
          <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Associated w/ High Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
        </group>
        <group group_id="B4">
          <title>High Dose (rhCC10)</title>
          <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Mean gestational age at birth (in weeks, SD)</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="1.3"/>
                    <measurement group_id="B2" value="26.5" spread="1.1"/>
                    <measurement group_id="B3" value="27.0" spread="1.3"/>
                    <measurement group_id="B4" value="26.6" spread="1.2"/>
                    <measurement group_id="B5" value="26.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Hispanic/Latino or unknown ethnicity by number of participants, n (%).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Number of participants, N(%)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Count of participants enrolled in the US (Tufts Medical Center, Brigham and Women's Hospital, Bay State Medical Center) and Poland (Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski, and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie). All three sites in Poland administered the high dose CC10/placebo cohorts only.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean birth weight</title>
          <description>in grams (SD)</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="877.4" spread="170.9"/>
                    <measurement group_id="B2" value="859.3" spread="140.9"/>
                    <measurement group_id="B3" value="885.5" spread="173.9"/>
                    <measurement group_id="B4" value="867.2" spread="187.2"/>
                    <measurement group_id="B5" value="874.5" spread="168.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median 5 min APGAR score</title>
          <description>Appearance, Pulse, Grimace, Activity, and Respiration (APGAR), a 5-criteria assessment used to summarize the health of the newborn against infant mortality, scored at 5 minutes after birth. Each assessment (Appearance, Pulse, Grimace, Activity, and Respiration) is scored on a categorical scale of 0, 1 or 2 based on given criteria. All assessment scores are summarized to create the APGAR score (min = 0, max = 10). An APGAR score ≥7 generally indicates a newborn with normal health; An APGAR score ≤3 is generally considered critically low and cause for resuscitation efforts and critical care.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="8"/>
                    <measurement group_id="B2" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="B3" value="7" lower_limit="7" upper_limit="8"/>
                    <measurement group_id="B4" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="B5" value="7" lower_limit="7" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA)</title>
        <description>Number of events of survived participants without one or more of the CPIP components defined below:
Medical/ER visits (CPIP-DV): At least one non-routine medical visit for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): One or more re-hospitalizations for respiratory causes.
Respiratory Symptoms (CPIP-SS): Evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications by parental diaries or pulmonary questionnaires.
Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen).
CPIP is defined as the presence of one or more parent-reported outcomes at 12 months CGA, validated by Respiratory diaries (presence of wheezing, coughing, and/or respiratory medication use ≥2 days per week for 3 consecutive weeks), and Pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
        <time_frame>12 Months Corrected Gestational Age (*no imputation for missing data)</time_frame>
        <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego (UM), Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Associated w/ Low Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O2">
            <title>Low Dose (rhCC10)</title>
            <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Associated w/ High Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 21 participants</description>
          </group>
          <group group_id="O4">
            <title>High Dose (rhCC10)</title>
            <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA)</title>
          <description>Number of events of survived participants without one or more of the CPIP components defined below:
Medical/ER visits (CPIP-DV): At least one non-routine medical visit for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): One or more re-hospitalizations for respiratory causes.
Respiratory Symptoms (CPIP-SS): Evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications by parental diaries or pulmonary questionnaires.
Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen).
CPIP is defined as the presence of one or more parent-reported outcomes at 12 months CGA, validated by Respiratory diaries (presence of wheezing, coughing, and/or respiratory medication use ≥2 days per week for 3 consecutive weeks), and Pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
          <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny Uniwersytetu Medycznego (UM), Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
          <units>Number of events</units>
          <param>Number</param>
          <units_analyzed>Number of events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survived with no CPIP-DV (Medical/ER visits)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived with no CPIP-RH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived with no CPIP-SS (Respiratory Symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived with no CPIP-RM (Respiratory Medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived with no CPIP events (-DV, -RH, -SS, -RM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long Term Efficacy - Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 6 Months Corrected Gestational Age (CGA)</title>
        <description>Number of events of survived participants, graded as not having 1, 2, 3, or 4 of the CPIP components defined below:
Medical/ER visits (CPIP-DV): ≥1 non-routine medical visit(s) for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): ≥1 re-hospitalization(s) for respiratory causes Respiratory Symptoms (CPIP-SS): Parent-reported evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen)
A participant graded without 4 CPIP components is considered in better health than a participant graded without 1 CPIP component. CPIP components were parent-validated via respiratory diaries (wheezing, coughing, and/or respiratory medication use ≥2 days/wk for 3 consecutive wks), and pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
        <time_frame>6 months Corrected Gestational Age</time_frame>
        <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Associated w/ Low Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O2">
            <title>Low Dose (rhCC10)</title>
            <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Associated w/ High Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
          </group>
          <group group_id="O4">
            <title>High Dose (rhCC10)</title>
            <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Long Term Efficacy - Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 6 Months Corrected Gestational Age (CGA)</title>
          <description>Number of events of survived participants, graded as not having 1, 2, 3, or 4 of the CPIP components defined below:
Medical/ER visits (CPIP-DV): ≥1 non-routine medical visit(s) for respiratory causes.
Respiratory re-hospitalizations (CPIP-RH): ≥1 re-hospitalization(s) for respiratory causes Respiratory Symptoms (CPIP-SS): Parent-reported evidence of respiratory symptoms (e.g. coughing and wheezing) or use of respiratory medications Respiratory Medications (CPIP-RM): Administration of respiratory medications (including oxygen)
A participant graded without 4 CPIP components is considered in better health than a participant graded without 1 CPIP component. CPIP components were parent-validated via respiratory diaries (wheezing, coughing, and/or respiratory medication use ≥2 days/wk for 3 consecutive wks), and pulmonary questionnaires (decrease in respiratory illness requiring medications, unscheduled medical visits and/or ER or hospital admissions).</description>
          <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survived without 1 CPIP component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived without 2 CPIP components</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived without 3 CPIP components</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived without 4 CPIP components</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Efficacy - Number of Participants With Adverse Events</title>
        <description>The safety of the study drug was assessed by accounting the number of participants with Adverse Events (AEs) in the treatment and placebo groups.</description>
        <time_frame>Adverse events are monitored through 36 wks post-menstrual age (PMA)</time_frame>
        <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Associated w/ Low Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O2">
            <title>Low Dose (rhCC10)</title>
            <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Associated w/ High Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 21 participants</description>
          </group>
          <group group_id="O4">
            <title>High Dose (rhCC10)</title>
            <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Efficacy - Number of Participants With Adverse Events</title>
          <description>The safety of the study drug was assessed by accounting the number of participants with Adverse Events (AEs) in the treatment and placebo groups.</description>
          <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term Efficacy - Number of Neonates With Oxygen Requirement at 36 Weeks Post Menstrual Age</title>
        <description>Short term efficacy evaluations involve number of neonates with oxygen requirement at 36 weeks post menstrual age.</description>
        <time_frame>36 weeks post-menstrual age</time_frame>
        <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Associated w/ Low Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
          </group>
          <group group_id="O2">
            <title>Low Dose rhCC10</title>
            <description>1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
Low Dose rhCC10: 1.5 mg/kg study drug (rhCC10)</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Associated w/ High Dose Cohort)</title>
            <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 21 participants</description>
          </group>
          <group group_id="O4">
            <title>High Dose rhCC10</title>
            <description>5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
High dose rhCC10: 5 mg/kg in 2 ml/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Short Term Efficacy - Number of Neonates With Oxygen Requirement at 36 Weeks Post Menstrual Age</title>
          <description>Short term efficacy evaluations involve number of neonates with oxygen requirement at 36 weeks post menstrual age.</description>
          <population>Subjects were recruited from Tufts Medical Center, Brigham and Women's Hospital, Baystate Medical Center, Ginekologiczno-Położniczy Szpital Kliniczny UM, Instytut Centrum Zdrowia Matki Polski and Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (USA, Poland).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A given participant was monitored for Adverse Events (AE) and Serious Adverse Events (SAE) for an average of 34 months. Note: Some infants experienced the same AE on multiple occasions.</time_frame>
      <desc>AEs and SAEs were reported according to std. definitions, except AEs specific to this population and possibly relevant to the drug were automatically categorized as SAEs, regardless of severity, so each event would generate a report and be reviewed by study staff and the Data Safety and Monitoring Board (DSMB). AEs selected for automatic SAE reporting included; sepsis, pneumonia, air leaks (pneumothorax, pulmonary interstitial edema, pneumomediastinum), and pulmonary hemorrhage.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Associated w/ Low Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="E2">
          <title>Low Dose (rhCC10)</title>
          <description>Dosage: 1.5 mg/kg study drug rhCC10 in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 22 participants</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Associated w/ High Dose Cohort)</title>
          <description>Dosage: Single dose of half normal saline at 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 21 participants</description>
        </group>
        <group group_id="E4">
          <title>High Dose (rhCC10)</title>
          <description>Dosage: 5 mg/kg of rhCC10 given in 2 ml/kg
Administration: once intratracheally within the first 24 hours of life, and once within 4 hours of the first dose of exogenous surfactant (CurosurfTM)
Enrollment: 23 participants</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>PDA</sub_title>
                <description>Patent ductus arteriosus</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ROP Stage 3</sub_title>
                <description>Retinopathy of prematurity</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NEC Stage II-III</sub_title>
                <description>Necrotizing enterocolitis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory Infections</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="19" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="17" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IVH grade 3-4</sub_title>
                <description>Intraventricular Hemmorhage</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PVL</sub_title>
                <description>Periventricular leukomalacia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary Interstitial Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E3" events="39" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E4" events="50" subjects_affected="18" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Coagulation disorders or circulatory insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>PDA +ASD</sub_title>
                <description>Patent Ductus Arteriosus and Atrial Septal Defect</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E4" events="18" subjects_affected="14" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ROP Stages I-IV</sub_title>
                <description>Retnoipathy of Prematurity</description>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NEC Grades I-IV</sub_title>
                <description>Necrotizing enterocolitis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hernia (inguinal)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" events="11" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>Urinary Tract Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bronchitis/ bronchiolitis/ tracheitis/laryngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Desaturation after study medication administration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IVH Grades I-IV</sub_title>
                <description>Intraventricular Hemmorhage</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PVL Grades I-IV</sub_title>
                <description>Periventricular Leukomalacia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PIE</sub_title>
                <description>Pulmonary Interstitial Emphysema</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan M. Davis, MD</name_or_title>
      <organization>Tufts Medical Center | Division of Newborn Medicine</organization>
      <phone>(617) 636-5322</phone>
      <email>jdavis@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

